FindTrial
Sign In

IBI305

DRUG4 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital

Conditions

Advanced Microsatellite Stable Colorectal CancerHepatocellular CarcinomaIntrahepatic CholangiocarcinomaMetastatic Microsatellite-stable Colorectal CancerNon-Squamous Non-Small Cell Lung Cancer

Phase 2

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
NCT03794440
Innovent Biologics (Suzhou) Co. Ltd.Hepatocellular Carcinoma
Start: 2019-02-11End: 2022-12-31Updated: 2021-01-22
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
NCT04724239
Sun Yat-sen UniversityAdvanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
Start: 2021-03-11End: 2023-12-31Updated: 2023-08-01
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
NCT05251662
Tianjin Medical University Cancer Institute and HospitalIntrahepatic Cholangiocarcinoma
Start: 2022-01-13End: 2025-01-13Target: 90Updated: 2022-02-23

Phase 3

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
CompletedNCT03802240
Innovent Biologics (Suzhou) Co. Ltd.Non-Squamous Non-Small Cell Lung Cancer
Start: 2019-07-11End: 2023-06-30Updated: 2023-11-27

Related Papers

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.
2025-06-232 citations
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.
2024-03-04118 citations
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
2023-05-05145 citations
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
2023-03-319 citations
ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma.
Journal of Clinical Oncology2023-01-247 citations
Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma.
Journal of Clinical Oncology2023-01-241 citations
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
2022-07-28168 citations
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
2021-06-15803 citations